LYTENAVA™ (bevacizumab gamma) — NDA/BLA submission
Oct 1
As part of these efforts, the Company plans to submit an application for a permanent Healthcare Common Procedure Coding System or HCPCS code by October 1, 2026, to support reimbursement following launch.Source filing